Teva Pharmaceutical Industries is planning to sell off assets and operations of Actavis Generics in the UK and Ireland to Intas Pharmaceuticals subsidiary Accord Healthcare for £603 million.
The move, which remains subject to final regulatory approval, is part of an agreement with the European Commission to sell off certain assets in various countries it acquired through its $40.5-billion purchase of Allergan’s global generics business.
The sale will include a portfolio of generic medicines plus a manufacturing plant in Barnstaple, England.
The remainder of the Allergan Generics UK/Ireland business will be integrated with Teva’s operations in line with the global transaction.
“With the assets that it will retain, Teva will create an even stronger operation in the UK and Ireland,” said Siggi Olafsson, president and chief executive of Global Generic Medicines Teva.
“Teva is the leading provider of medicines to the UK National Health Service, and the addition of the retained Actavis assets strengthens our ability to be the partner of choice in these countries while preserving strong and healthy competition in a competitive marketplace.”
By Selina McKee
Source: Pharma Times
The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) has introduced several new measures to make it easier to run clinical trials in the country, marking the first time in 20 years the regulatory body has made such an overhaul.
Diabetes drugmaker Novo Nordisk is partnering with Dewpoint Therapeutics in a deal aimed at uncovering new treatments for insulin resistance by targeting cellular droplets known as biomolecular condensates. Dewpoint will receive $55 million upfront from Novo, which plans to develop small molecule drugs against targets discovered using Dewpoint’s technology.
Sanofi has secured approval for Dupixent (dupilumab) from the European Commission (EC) to treat severe atopic dermatitis in children aged six months to five years, who are systemic therapy candidates, in the European Union (EU). This approval makes Dupixent the first and only medicine available in the US and Europe for the treatment of such young children.
